Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,947 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis.
Ahmed GU, Ramsha F, Kinger S, Shaikh JG, Prejna F, Ritik F, Shabir I, Suhail F, Basit MA, Moiz M, Ali A, Manan A, Samadi A, Raza AA. · Brain Behav · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.
Khani-Habibabadi F, Verhamme FM, Moshir M, Casneuf T, Rao VTS, Steeland S, Ulrichts P, Pham MC, Nowak RJ, Roy B, O'Connor KC. · J Neurol Neurosurg Psychiatry · 2026 · cited 0 timesclinical trial, phase iii, randomized controlled trial
- Long‑term disease control in generalized myasthenia gravis: a systematic literature review.
Casasnovas C, Claeys KG, Saccà F, Verbiest T, Gary C, Noel W, Hardy EJ, Brodie-Farmer M, Mitchell SA, Vissing J. · BMC Neurol · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta-Analysis, and Meta-Regression.
Nelke C, Skrobol M, Theissen L, Sacca F, Ruck T. · Eur J Neurol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review.
Gilhus NE, Melsom SC, Bugge C. · J Neurol · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.
Gwathmey KG, Saccà F, Howard JF, Vu T, Xi J, Mäurer M, Ruck T, Shin HY, Takahashi MP, Casasnovas C, Smilowski M, Peric S, Masuda M, Scholz J, Shang S, Yee M, Rakhade S, Annane D. · JAMA Neurol · 2026 · cited 4 timesOpen accessclinical trial, phase iii, multicenter study
- Very late-onset myasthenia gravis: a systematic review and meta-analysis of clinical severity and long-term outcomes.
Liampas I, Demiri S, Polyviou A, D'Orsi A, Siokas V, Veltsista D, Dardiotis E, Chroni E. · Eur Geriatr Med · 2026 · cited 0 timesmeta-analysis, systematic review
- Co-Occurrence of Facioscapulohumeral Muscular Dystrophy and Myasthenia Gravis: A Systematic Review and Meta-Analysis of Individual Patient Data.
Gunawan PY, Wijaya JH. · Eur J Neurol · 2026 · cited 0 timesmeta-analysis, systematic review
- Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial.
Nowak RJ, Utsugisawa K, Benatar M, Ciafaloni E, Leite MI, Vissing J, Tang F, Wu Y, Najem C, Cheng S, Howard JF, MINT investigators. · JAMA Neurol · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Clinical research on ocular myasthenia gravis and related neuromuscular disorders: A systematic review and overview.
Wang M, Sheng Z. · Clin Invest Med · 2026 · cited 0 timessystematic review
- Telitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safety.
Zhang W, Wang Y, Qiao W. · Front Neurol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial.
Saccà F, Gialdini G, Howard JF, Vu TH, Meisel A, Peric S, Lünemann JD, Sgarzi M, Shaibani A, Bril V, Yeh JH, Reyes-Garrido V, Liao S, Metais C, van der Valk RJP, ALXN2050-MG-201 Investigators. · JAMA Neurol · 2026 · cited 3 timesclinical trial, phase ii, multicenter study
- Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis.
McLaren NP, Rosati M, Zhong W, Hussain S, Funaro MC, Nowak RJ, Roy B. · Neurology · 2026 · cited 0 timescomparative study, network meta-analysis
- Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study.
Claeys KG, Yang H, Gandhi K, Turkoz I, Fitzgibbon M, Pease S, Ramchandren S. · Expert Opin Biol Ther · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Myasthenia gravis and pregnancy: a systematic review and meta-analysis.
Miegel L, Hickstein J, Reibelt A, Heesen C, Schubert C. · J Neurol · 2026 · cited 2 timesOpen accessmeta-analysis, systematic review
- Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.
Verza MU, Schiavolin M, Beretta F, Cornacchini S, Lotti A, Spagni G, Damato V. · Muscle Nerve · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Immunoglobulin for myasthenia gravis.
Manolopoulos A, Alzuabi M, Elmashala A, Cashwell J, Murad MH, Naddaf E. · Cochrane Database Syst Rev · 2025 · cited 8 timesmeta-analysis, systematic review
- Very late-onset myasthenia gravis: a systematic review and meta-analysis of sex distribution, thymic pathology and autoantibodies.
Liampas I, Demiri S, Malataras G, Polyviou A, Siokas V, Veltsista D, Dardiotis E, Chroni E. · J Neurol · 2026 · cited 1 timesmeta-analysis, systematic review
- Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review.
Soriano J, Martínez-Rubiño M, Vicente Elcano M, Pellicer Pérez M, Bergua de Roque A, Tanco Mulero S, Miquel Bosh C, Chen-Ye A, Martín Ruiz D, Torras-Vigo I, Pellicer-Boiges A, Ble Gimeno M, Navarro-Gorro N, Belarte-Tornero LC, Visa L, Taus Á, Rodriguez Martínez JE, Rodriguez-Vida A, Arriola E, Llaberia-Torrelles M. · Support Care Cancer · 2026 · cited 0 timessystematic review
- Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.
Vissing J, Coteur G, Turkoz I, Gandhi K. · J Med Econ · 2026 · cited 0 timesrandomized controlled trial
- Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.
Gilbert K, Cheema AK, Kaminski HJ, Kusner LL. · J Transl Med · 2026 · cited 0 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Effectiveness and safety of efgartigimod in myasthenia gravis: A meta-analysis of different antibody subtypes.
Sabet H, AbuHamdia A, Zanaty MA, El-Moslemani M, Ewis DK, Elyamany Z, Khatatbeh A, Almarfadi A, Al-Rayess H, Altalab G, Aldehri M, Al-Fawzan FF, Shaban EA, Abbas A. · Immunol Res · 2026 · cited 0 timesmeta-analysis
- Association between vaccination and myasthenia gravis: a systematic review and meta-analysis.
Guan C, Zhang R, Zhao P, Zhang Y, Yu L, Cui H, Jiang L, Wu T, Liu F, Wu Y, Huang L, Nan H, Wang J, Xu P. · Front Immunol · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.
Vissing J, Pease S, Scippa K, Gandhi K, Ramchandren S, Grover K, Huang D, Watanabe G. · J Neurol · 2026 · cited 0 timesclinical trial, phase iii, randomized controlled trial
- Rituximab for myasthenia gravis.
Dodd KC, Clay FJ, Forbes AM, Handley J, Keh RYS, Miller JA, Storms K, White LM, Lilleker JB, Sussman J. · Cochrane Database Syst Rev · 2025 · cited 9 timesmeta-analysis, systematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.